Investor Relations Home

About Natera

About Natera

Natera is a rapidly-growing diagnostics company with proprietary bioinformatics and molecular technology for analyzing DNA. Natera’s complex technology has been proven clinically and commercially in the prenatal testing space and the Company is actively researching its applications in the liquid biopsy space for developing products with oncology applications.

Since 2009, Natera has launched seven molecular diagnostic tests, many of which are available through major health plans accounting for more than 140 million covered lives in the United States. The Company’s own robust laboratory processes thousands of genetic tests per month.

Natera’s goal is to transform the way people – both providers and patients – respond to and manage genetic diseases.

Learn More About Natera

Stock Information

NTRA (Common Stock)
ExchangeNASDAQ CM (US Dollar)
Change (%) Stock is Up 0.11 (0.00%)
Data as of 10/17/18 4:00 p.m. ET
Minimum 15 minute delay
Refresh quote
Stock chart for: NTRA.O.  Currently trading at $21.33 with a 52 week high of $29.62 and a 52 week low of $8.60.

Recent News

Natera Signs Agreement with Bristol-Myers Squibb to Investigate Signatera™ ctDNA Assay as a Potential Biomarker for Opdivo (nivolumab) in a Prospective Phase 2 Adjuvant Non-Small Cell Lung Cancer Clinical Trial - 09/13/18
First Study Using ctDNA-based Minimal Residual Disease Assessment for Immunotherapy in the Adjuvant NSCLC Setting SAN CARLOS, Calif., Sept. 13, 2018 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today ann... More»
Natera and Fox Chase Cancer Center to Collaborate on Kidney Cancer Study - 08/15/18
SAN CARLOS, Calif., Aug. 15, 2018 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, has partnered with Fox Chase Cancer Center, one of the leading cancer centers in the United States, to assess the company's Signa... More»
Natera Reports Second Quarter 2018 Financial Results - 08/08/18
SAN CARLOS, Calif., Aug. 8, 2018 /PRNewswire/ -- Natera, Inc. (NASDAQ:  NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today reported financial results for the second quarter ended June 30, 2018 and pro... More»
Natera Clinical Study Validates New Biomarker for Aneuploidy and Adverse Pregnancy Outcomes - 08/07/18
Study Highlights Proprietary Technology for Fetal Fraction Measurement in Non-Invasive Prenatal Testing SAN CARLOS, Calif., Aug. 7, 2018 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing, today announced new s... More»
Study Shows Natera's Spectrum Preimplantation Genetic Testing for Aneuploidy Improves IVF Outcomes for All Women, Regardless of Maternal Age - 08/02/18
SAN CARLOS, Calif., Aug. 2, 2018 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing, today announced the publication of a study demonstrating the value of the company's Spectrum® preimplantation genetic screening fo... More»

Upcoming Events

There are currently no events scheduled.

The information provided in this area of the website is maintained by a third-party service. Natera is not responsible for the accuracy, currency or completeness of the information contained herein.
Data provided by Nasdaq. Minimum 15 minutes delayed.